Drug or technology
8 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release capsules; this is a regulatory action, not a clinical evidence trial.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for morphine sulfate REMS program; establishes risk management requirements but does not report clinical trial efficacy or comparative outcomes.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release tablets; this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial data.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing morphine sulfate oral solution; regulatory action does not establish clinical efficacy or comparative benefit.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release capsules; indicates regulatory action to manage known risks but does not report clinical trial outcomes or efficacy data.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release tablets; regulatory action record without clinical trial data.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release capsules; this is a regulatory action establishing safety management requirements, not a clinical efficacy study.
MAY 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of morphine sulfate labeling; regulatory action does not report clinical trial outcomes or efficacy data.